Audentes Therapeutics (BOLD) Receives a Buy from Chardan Capital

By Austin Angelo

In a report released yesterday, Gbola Amusa from Chardan Capital reiterated a Buy rating on Audentes Therapeutics (BOLDResearch Report), with a price target of $50. The company’s shares closed last Monday at $31.10.

According to TipRanks.com, Amusa is a 5-star analyst with an average return of 18.1% and a 49.4% success rate. Amusa covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Catalyst Biosciences Inc, and Voyager Therapeutics Inc.

Currently, the analyst consensus on Audentes Therapeutics is a Moderate Buy with an average price target of $42.17.

See today’s analyst top recommended stocks >>

The company has a one-year high of $41.65 and a one-year low of $17.95. Currently, Audentes Therapeutics has an average volume of 417.8K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Audentes Therapeutics, Inc. is a biotechnology company, which engages on development and commercialization of gene therapy products for patients with serious and rare diseases caused by single gene defects. Its products include AT001 for the treatment of X-Linked Myotubular Myopathy, AT002 for the treatment of Pompe disease, and AT003 for the treatment of Catecholaminergic Polymorphic Ventricular Tachycardia. The company was founded by Matthew R. Patterson and Thomas J. Schuetz on November 13, 2012 and is headquartered in San Francisco, CA.